- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| Fr | William Blair upgrades Biodesix stock rating on execution momentum | 2 | Investing.com | ||
| Fr | William Blair stuft Biodesix hoch: Starke Geschäftsentwicklung überzeugt | 6 | Investing.com Deutsch | ||
| Fr | Biodesix, Inc. Q4 Loss Drops | - | RTTNews | ||
| Fr | Biodesix outlines $106M-$112M 2026 revenue target as sales expansion drives 41% Q4 growth | 2 | Seeking Alpha | ||
| Do | Biodesix GAAP EPS of -$0.49 beats by $0.38, revenue of $28.7M beats by $2.45M | 1 | Seeking Alpha | ||
| Do | Biodesix Earnings Report: Q4 Overview | 1 | Benzinga.com | ||
| Do | BIODESIX INC - 10-K, Annual Report | 1 | SEC Filings | ||
| Do | Biodesix, Inc.: Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights | 155 | GlobeNewswire (Europe) | Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million,... ► Artikel lesen | |
| Do | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 12.02. | Biodesix, Inc.: Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 1 | GlobeNewswire (USA) | ||
| 06.02. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.01. | Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More | 4 | Insider Monkey | ||
| 13.01. | Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability | 4 | Investing.com | ||
| 12.01. | Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results | 5 | RTTNews | ||
| 12.01. | Biodesix skyrockets 43%, expects FY revenue to beat guidance | 4 | Seeking Alpha | ||
| 12.01. | Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance | 3 | Investing.com | ||
| 12.01. | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | 174 | GlobeNewswire (Europe) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| 03.12.25 | Biodesix, Inc.: Biodesix to Present New Data at Two Major Upcoming Scientific Meetings | 2 | GlobeNewswire (USA) | ||
| 04.11.25 | Biodesix: Canaccord bestätigt Kaufempfehlung nach starken Q3-Zahlen | 2 | Investing.com Deutsch | ||
| 04.11.25 | Biodesix stock maintains Buy rating at Canaccord after strong Q3 results | 1 | Investing.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | +1,38 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| VALNEVA | 4,700 | -0,63 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,990 | -1,97 % | HEIDELBERG PHARMA AG im strukturellen Gleichgewicht | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INFLARX | 0,774 | -0,71 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,645 | -0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| TEMPUS AI | 45,000 | -0,44 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| GENMAB | 246,90 | -0,72 % | Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise | The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as of 27 February 2026 in the ISIN below.
ISIN:
DK0010272202
Name:
Genmab
Volume... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,444 | +0,56 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,342 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,88 | +1,23 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| EXELIXIS | 37,260 | -0,11 % | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,438 | +0,86 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans |
BIODESIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +10,54 % bei einem Aktienkurs von 15,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.